17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
Tel.: (91-22) 6645 5645
Fax.: (91-22) 6645 5685

FOR IMMEDIATE RELEASE

Sun Pharma announces USFDA approval to market generic Protonix ® Tablets

Company gets its first 180 day marketing exclusivity on a first-to-file ANDA with para IV certification

Mumbai, September 11, 2007: Sun Pharmaceutical Industries Ltd. announced that USFDA has granted final approval for the company's Abbreviated New Drug Application (ANDA) to market its generic version of Wyeth's Protonix ®, pantoprazole tablets.

These generic pantoprazole tablets are AB-rated equivalent of Wyeth's Protonix ® Delayed Release Tablets and include two strengths: 20 mg (base) and 40 mg (base). These strengths of Protonix® have annual sales of approximately USD 2.3 billion in the US.

Sun Pharma, being one of the first-to-file an ANDA for generic Protonix® with a para IV certification, shares a 180-day marketing exclusivity.

Pantoprazole is indicated for short term treatment of erosive esophagitis associated with GERD, maintenance of healing of erosive esophagitis and for treatment of hypersecretory conditions.

The Company is currently evaluating its launch options.

PROTONIX ® is a registered trademark of Wyeth Pharmaceuticals Inc

About Sun Pharma

Established in 1983, listed since 1994 and headquartered in India, Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

Contacts

Uday Baldota
Tel +91 22 6645 5645, Xtn 605
Tel Direct +91 22 66455605
Mobile +91 98670 10529
E mail uday.baldota@sunpharma.com

Mira Desai
Tel +91 22 6645 5645, Xtn 606
Tel Direct +91 22 66455606
Mobile +91 98219 23797
E mail miradesai@sunpharma.com